| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Chronic lymphocytic leukemia
Testing for prognosis and risk stratification
The need for all-encompassing testing for patients with chronic lymphocytic leukemia is of the utmost importance for managing the progressive illness and is recommended by the National Comprehensive Cancer Network (NCCN) and International Workshop on Chronic Lymphocytic Leukemia (IWCLL). Because treatment decisions are based on symptom severity of the illness, advanced testing aids clinicians in diagnosing, monitoring, and managing treatment for patients who have CLL.
Mayo Clinic Laboratories’ approach to CLL testing meets all testing recommendations — including molecular testing for IGHV and TP53 mutations — as well as comprehensive fluorescence in situ hybridization (FISH) panels, which detect for genetic biomarkers associated with disease severity, progression, and treatment response. Because all testing is performed at one facility, the need for splitting patient samples is reduced, and continuity of care is increased.
Comprehensive testing simplified
The need for all-encompassing testing for patients with chronic lymphocytic leukemia is of the Our approach to fluorescence in situ hybridization (FISH)testing is designed to simplify the ordering process by providing diagnostic panels that include all appropriate genes.
Key testing
IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)
Our goals today are, first of all, to understand the use of prognostic markers in CLL patients; second, to highlight the importance of molecular analyses for IGHV and TP53 sequencing in CLL patients; third, to understand how IGHV mutation analysis provides prognostic information in CLL and can help inform clinicians about possible treatment decisions; and finally, to recognize that TP53 mutations identified by sequencing studies are associated with poor outcomes, since those patients are more likely to be resistant to standard therapeutic regimens.
Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable (IGHV) gene mutation when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.
